Inhaled Product Characterization - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inhaled Product Characterization
The authors discuss the analysis of the resulting data, focusing on methods for the calculation of mass median ærodynamic diameter, one of the metrics routinely used for comparative testing.

Pharmaceutical Technology
pp. s33-s37

Using cascade impaction data

Once the raw data are gathered, the question arises of how best to use them to meet testing requirements. The industry has a number of routinely applied metrics, including MMAD, fine particle dose or fraction (FPD or FPF), and geometric standard deviation (GSD). Of these, MMAD, the particle size below which 50% of the particle population lies on the basis of mass, is probably the most widespread, although acceptance criteria are typically based on mass-per-stage or fine particle dose (FPD) applicable to the active. Together, MMAD and GSD locate the central point of the APSD and describe its spread, thereby summarising the key features of what is most often a monomodal particle-size distribution.

During drug development, the aim is to formulate towards a predetermined delivery of the active. The particle-size distribution of the delivered dose is closely connected with the delivery efficiency because it influences deposition within the lungs. In general, particles above 5 μm in diameter are considered too large for pulmonary deposition; for the deep lung, even finer particles may be preferred, perhaps 2–3 μm (3). The lower size limits of OINDP formulations are usually of much less concern, although research suggests that a high proportion of sub-micron particles may be an effective means of achieving bronchodilation, thereby enhancing the efficiency of drug delivery (4).

APSD data support the manipulation of a device or formulation towards desirable performance. FPD or fine particle fraction (FPF), the amount or fraction of the delivered dose that lies below the 5 μm range, is a useful metric; achieving an MMAD of 2–3 μm is a frequent goal. A relatively low MMAD coupled with a low GSD is indicative of a tight size distribution centred on a fine particle size, a potentially beneficial combination for efficient delivery.

Once a product transitions into manufacture, detecting any differences between manufactured material and the defined specification becomes critical for quality assurance. The same metrics may be used to summarize APSD data because they focus attention on those features of the distribution that are especially crucial in terms of the delivery to the patient and, by inference, clinical efficacy. It is important to recognize, however, that regulators currently request full resolution data rather than single number metrics to verify product quality, just as they do to support a new drug application.

Most testing, therefore, is comparative, against a predetermined target (i.e., development) or a specification (i.e., QC). Overlaying two distributions shows up differences but not necessarily in a particularly informative way. However, the metrics identified are indicative not only of the difference but also of relative performance, which explains their popularity.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here